EXPLOSIVE GROWTH OF E-CIGARETTE SCIENCE

Posted by Giovanni Ciavarra on Posted on

It is our experience that many attorneys and their teams struggle to keep up with new science in a systematic and organized fashion. However, we have also encountered scientific savvy firms that are up-to-date on the science and hard at work analyzing and developing new legal strategies based on the emerging science. This latter group
Read More

Key Takeaways from Recent Talc Powder ‘Science Day’ Hearing in California

Posted by David Schwartz on Posted on

“Science Day” hearings have become commonplace in complex state and federal litigations around the country. A California state court judge recently held such a hearing in consolidated litigation dealing with the alleged link between talcum powder and ovarian cancer. With a bellwether trial scheduled for July, the closely-watched hearing was webcast and recorded by Courtroom
Read More

Experts On The Experts: A Deep Dive Into The Make-or-Break Scientific Testimony Deciding Talc Powder Trials

Posted by David Schwartz on Posted on

This article previously appeared on Courtroom View Network.
Read More

Will EU Regulatory Battles Over Endocrine Disruptors Translate to US Litigation?

Posted by David Schwartz on Posted on

There is a battle raging in the European Union on an issue that is recognized in the US only by environmental scientists, policy wonks, and activists: the regulatory status of endocrine disrupting chemicals. As we have written before, this debate could have dramatic implications for litigation in the US. Such litigation could involve claims that
Read More

USING GENOMICS TO PREVAIL IN YOUR NEXT TOXIC TORT CASE

Posted by David Schwartz on Posted on

As any good toxic tort litigator knows, it is not enough for a defendant to demonstrate that the alleged harmful chemical was not the cause of the injury. Rather, an effective defense provides the jury with a reasonable explanation as to what the cause of the injury was. Genomic data offer the defense just such
Read More

Adverse Drug Events from Social Media: 4 Reasons Pharmaceutical and Medical Device Companies Need to have a Plan

Posted by Giovanni Ciavarra on Posted on

This article was co-authored by Josephine Borrillo, a Digital Health Consultant that advises healthcare enterprises on best practices for the development, adoption, and marketing of digital health technologies.
Read More

Was There Exposure? Objective Tests Through Advances in Biomarker Science Relevant to Asbestos and Other Toxic Tort Litigation

Posted by Giovanni Ciavarra on Posted on

This article was authored by Giovanni Ciavarra, PhD and Kirk Hartley, Esq.  This post previously appeared on The Goldberg Segalla Asbestos Case Tracker.
Read More

WEBINAR: Genetic Susceptibility, Exposure Markers, and the Talc Experience

Posted by David Schwartz on Posted on

Innovative Science Solutions will be speaking at the upcoming Toxic Torts and Product Liability Webinar to be hosted by Mayer Brown on Thursday, January 19, 2017 (1:00 p.m. – 2:30 p.m. EST).   Emerging Science and Toxic Tort Litigation: Genetic Susceptibility, Exposure Markers, and the Talc Experience   The webinar features a presentation by Dr.
Read More

Does Carcinogenicity Classification Make Any Sense?

Posted by David Schwartz on Posted on

In a recent trial involving allegations that asbestos-contaminated talc caused the plaintiff’s mesothelioma (the Lamonica case), plaintiff counsel (Scott Frost) was having a difficult time impeaching the opinions of the defense pathologist (Dr. Mossman). After spending some time trying to impeach her opinions based on her financial payments, Frost turned to another tried and true
Read More

Jurors in Toxic Tort Litigation Take Genetic Issues Seriously

Posted by David Schwartz on Posted on

This article was authored by David Schwartz, PhD and Kirk Hartley, Esq.  This post previously appeared on The Goldberg Segalla Asbestos Case Tracker.
Read More